Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Healthtrust
McKinsey
McKesson
Baxter
Argus Health
Boehringer Ingelheim
Johnson and Johnson
AstraZeneca

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,536,163

« Back to Dashboard

Which drugs does patent 8,536,163 protect, and when does it expire?

Patent 8,536,163 protects PICATO and is included in one NDA.

This patent has twenty-eight patent family members in twenty countries.
Summary for Patent: 8,536,163
Title:Therapeutic compositions
Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.
Inventor(s): Brown; Marc Barry (Watford, GB), Crothers; Michael (Hillsborough, GB), Nazir; Tahir (Isleworth, GB)
Assignee: LEO Laboratories Limited (Dublin, IE)
Application Number:13/769,821
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,536,163
Patent Claim Types:
see list of patent claims
Use; Formulation;

Drugs Protected by US Patent 8,536,163

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-001 Jan 23, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS ➤ Try a Free Trial
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-002 Jan 23, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,536,163

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0525680.5Dec 16, 2005

Non-Orange Book US Patents Family Members for Patent 8,536,163

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,603,822 Therapeutic compositions ➤ Try a Free Trial
8,372,828 Therapeutic compositions ➤ Try a Free Trial
8,278,292 Therapeutic compositions ➤ Try a Free Trial
8,735,375 Therapeutic compositions ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,536,163

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006325244 ➤ Try a Free Trial
Brazil PI0619919 ➤ Try a Free Trial
Canada 2634073 ➤ Try a Free Trial
Cyprus 1115292 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
UBS
Medtronic
McKinsey
Argus Health
Cerilliant
Daiichi Sankyo
Queensland Health
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.